ArticleOncogene2006
Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 137 citations in OpenAlex.
- "Cytokine-Mediated tumor sensitization: mechanistic frameworks and therapeutic opportunities in cancer Immunotherapy".Clinical and experimental medicine · 2026Review
- Investigating the biology of microRNA links to ALDH1A1 reveals candidates for preclinical testing in acute myeloid leukemia.International journal of oncology · 2024Review
- HER2 phosphorylation induced by TGF-β promotes mammary morphogenesis and breast cancer progression.The Journal of cell biology · 2024Article
- A narrative review of the relationship between TGF-β signaling and gynecological malignant tumor.Annals of translational medicine · 2021Review
- The Toxic Impact of Honey Adulteration: A Review.Foods (Basel, Switzerland) · 2020Review
- Sialylation of vasorin by ST3Gal1 facilitates TGF-β1-mediated tumor angiogenesis and progression.International journal of cancer · 2019Article
- Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.Journal of experimental & clinical cancer research : CR · 2019Article
- Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling.Theranostics · 2019Article
- Genetic Modifiers of the Breast Tumor Microenvironment.Trends in cancer · 2018Review
- TGF-β, Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment.Cold Spring Harbor perspectives in biology · 2017Review
- Transforming growth factor-β1 activates ΔNp63/c-Myc to promote oral squamous cell carcinoma.Oral surgery, oral medicine, oral pathology and oral radiology · 2016Article
- Constitutively active transforming growth factor β receptor 1 in the mouse ovary promotes tumorigenesis.Oncotarget · 2016Article
- Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.Drug design, development and therapy · 2015Review
- Links between cancer stem cells and epithelial-mesenchymal transition.OncoTargets and therapy · 2015Review
- Increased Expression of TGF-β Signaling Components in a Mouse Model of Fibrosis Induced by Submandibular Gland Duct Ligation.PloS one · 2015Article
- Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.Breast cancer research : BCR · 2014Article
- Therapeutic targeting of integrin αvβ6 in breast cancer.Journal of the National Cancer Institute · 2014Article
- Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.Molecular cancer · 2014Article
- TGF-β: duality of function between tumor prevention and carcinogenesis.Journal of the National Cancer Institute · 2014Review
- When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.Cells · 2014Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
We have examined the effects of transforming growth factor-beta (TGFbeta) signaling on mammary epithelial cell survival. Transgenic mice expressing an active mutant of Alk5 in the mammary gland (MMTV-Alk5(T204D)) exhibited reduced apoptosis in terminal endbuds and during postlactational involution. Transgene-expressing mammary cells contained lower Smad2/3 and higher c-myc levels than controls, high ligand-independent phosphatidylinositol-3 kinase (PI3K) and Akt activities, and were insensitive to TGFbeta-mediated growth arrest. Treatment with a proteasome inhibitor increased Smad2/3 levels and ligand-independent Smad transcriptional reporter activity, as well as reduced both c-myc protein and basal cell proliferation. Treatment with an Alk5 kinase small-molecule inhibitor upregulated Smad2/3 levels, reduced PI3K activity, P-Akt, and c-myc, and inhibited cell survival. Although Alk5(T204D)-expressing mice did not develop mammary tumors, bigenic MMTV-Alk(T204D) x Neu mice developed cancers that were more metastatic than those occurring in MMTV-Neu transgenics. These data suggest that (1) TGFbeta can signal to PI3K/Akt and enhance mammary epithelial cell survival in vivo before cytological or histological evidence of transformation, and (2) TGFbeta signaling can provide epithelial cells with a 'gain-of-function' effect that synergizes with oncogene-induced transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.